Coronavirus (COVID-19) ACEi/ARB Investigation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 2414 participants.

Also called NCT04330300

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,414 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04330300
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ireland (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04330300. Randomized; no masking; primary purpose prevention. Start 2020-04-30 (actual); primary completion 2021-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Coronavirus (COVID-19) ACEi/ARB Investigation
Acronym
CORONACION
Condition
Hypertension
Condition
COVID-19
Intervention (Drug)
Thiazide or Thiazide-like diuretics
Intervention (Drug)
Calcium Channel Blockers
Intervention (Drug)
ACE inhibitor
Intervention (Drug)
Angiotensin receptor blocker
Lead sponsor
National University of Ireland, Galway, Ireland (class: other)

Record details

Record id
cardio:ct-nct04330300
Content hash
fb8fb1f119c3ebeaae0d603467e42708663e1a0e2d6ac485e36e344662427f79